Application of molecular genetics in public health: improved follow-up in a neonatal hemoglobinopathy screening

Y H Zhang1, L L McCabe, M Wilborn

  • 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030.

Biochemical Medicine and Metabolic Biology
|June 1, 1994
PubMed

Insights

Molecular genetic testing in newborn screening for hemoglobinopathies, like sickle cell anemia, significantly speeds up diagnosis. This allows for earlier penicillin prophylaxis, reducing infant morbidity and mortality.

Area of Science:

  • Medical Genetics
  • Molecular Biology
  • Neonatal Screening

Background:

  • Newborn screening for hemoglobinopathies reduces infant morbidity and mortality.
  • Early penicillin prophylaxis by 4 months is crucial for managing sickle cell anemia.
  • Timely diagnostic confirmation is essential for effective newborn screening programs.

Purpose of the Study:

  • To assess the feasibility of integrating molecular genetic follow-up testing into neonatal hemoglobinopathy screening.
  • To determine if molecular genetic testing reduces the time to diagnostic confirmation.

Main Methods:

  • Compared allele-specific cleavage (ASC) with allele-specific oligonucleotide (ASO) hybridization for molecular genetic analysis.
  • Utilized dried blood specimens from the Texas Neonatal Hemoglobinopathy Screening Program.
  • Developed an automated microtiter plate-based method for ASC analysis.

Main Results:

  • Molecular genetic analyses were definitive for 506 out of 518 specimens.
  • ASC and ASO hybridization showed agreement in all analyzed specimens.
  • Rapid molecular genetic analysis reduced the mean age at confirmation by approximately 50% to 2 months.
  • Identified approximately 13% of screened FS individuals as probable S/beta-thalassemia.

Conclusions:

  • Allele-specific cleavage (ASC) is a reliable method for molecular genetic analysis of dried blood specimens.
  • Automated ASC methods can reduce labor, costs, and increase throughput.
  • Molecular genetic analysis of newborn screening specimens significantly reduces diagnostic confirmation time, ensuring prophylaxis before 4 months of age.

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...